All News

Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA) #ACR21 https://t.co/7leGTjm4fb
Rheum Cat rheum_cat ( View Tweet)
@AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth setting. Small improvement over time but still <50% 😱 Abstr#0146 #ACR21 @RheumNow https://t.co/FDp7ZwzfO5
Richard Conway RichardPAConway ( View Tweet)
Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement ⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo ⬇️MMP3 (associated with joint damage), C4M Abs#490 #ACR21 @RheumNow https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Skin Findings in Patients of Color with Rheumatic Disease #ACR21. Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW
Sali Merjanah SMerjanah ( View Tweet)
Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment ⬆️ACR20, 50, 70 response vs. pbo ⬆️secondary outcomes vs. pbo ⬆️serious AE vs. pbo, ⬆️zoster ⭐️no MACE/VTE/death reported Abs#488 #ACR21 @RheumNow https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5
Janet Pope Janetbirdope ( View Tweet)
Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at #ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abst 0482 Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement #ACR21 @RheumNow https://t.co/a00g3HMrM0
Akhil Sood MD AkhilSoodMD ( View Tweet)
🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin score and FVC! Abstr#496 #ACR21 @RheumNow #ACRBest https://t.co/Ta6Cq8XZie
Richard Conway RichardPAConway ( View Tweet)
Lots of excellent abstracts at #ACR21 on assessment & impact of #comorbidities & #multimorbidity in RA, some discussed in this article @RheumNow: https://t.co/WXgv1GmHD6 Featured abstracts: #0798 https://t.co/02BRqYp9Yk #1450 https://t.co/iG2s2Cy8Q0 #1924 https://t.co/qHws6ALENH

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT designs to treat pts MORE likely to respond. Also for an individual, following ANCA is not that helpful for altering Rx Take a look at this session GS401 #ACR21 #ACRBest @RheumNow https://t.co/nrapO9i4gw
Janet Pope Janetbirdope ( View Tweet)
Abst 0478 Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand OA - Identified 5 Phenotypes - Symptoms correlated with metabolic syndrome, joint destruction & physical and psychological burden #ACR21 @RheumNow https://t.co/O9hweqNIS8
Akhil Sood MD AkhilSoodMD ( View Tweet)
Bimekizumab (IL-17A and IL-17Fi) 3 year safety and efficacy in PsA Phase IIb trial ⭐️no new safety signals ⭐️candida infections were all mild/moderate ⭐️efficacy consistent and maintained Abs#491 #ACR21 @RheumNow https://t.co/BK6xPMqAEM https://t.co/meoPd7k0Xp

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at
Pedro Castillo _Castillo_Pedro ( View Tweet)
More from Dr. Atul Deodhar on treatment of axSpA and axPsA. Guselkumab studies DISCOVER 1 & 2 looked at PsA with sacroiliitis and demonstrated improved measures of axial activity, but we need more studies and to include MR imaging. #ACR21 6S403 session @RheumNow https://t.co/8jM5Fj8MuD
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abst 0370 #ACR21 @rheum survey of PCPs reveals lack of awareness about inflammatory back pain: 58%never/rarely assess for IBP; 40% not comfortable with making the dx of IBP. 83%never/rarely ordered HLAB27, 65% never/ rarely ordered CRP, 72% rarely/never ordered X-ray SI joint

Olga Petryna DrPetryna ( View Tweet)

New therapies this year in rheumatology #ACR21 year in review Avacopan in AAV and Voclosporin in Lupus nephritis @RheumNow @karen_kc123 https://t.co/8Z28STMJ6X
Bella Mehta bella_mehta ( View Tweet)
Using machine learning to predict knee cartilage worsening over 2 years sing gait and physical activity using the MOST study #abst0210 #ACR21 @RheumNow https://t.co/0MAjLhpL7t
Bella Mehta bella_mehta ( View Tweet)
Overlap between RA and SLE: is the famous rhupus more frequent than it seems? In the Boston OM1 SLE Registry w/ 44,186 SLE: 4.7% also reported as having RA. This is higher than the usual reported prevalence. #ACR21 #Abst0354 @RheumNow https://t.co/FYfvSdCkkF https://t.co/ISuae2hCI3

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Abst 0281 England & colleagues used unsupervised ML to determine whether peripheral biomarkers can accurately identify RA-ILD in large RA cohort - Identified 8 unique groups based on biomarkers - RF, anti-CCP, and -MAA biomarkers most closely associated w/ ILD https://t.co/831tP4JSh0
Akhil Sood MD AkhilSoodMD ( View Tweet)
×